Evidence map›Paper›PMID 35764433›Full record

ArticleVaccine2022

A national survey of COVID-19 vaccine acceptance in Nigeria.

Ahmad Ibrahim Al-Mustapha, Ochulor Okechukwu, Ademola Olayinka, Oyeniyi Rasheed Muhammed, Muftau Oyewo, Samuel A Owoicho, Ahmed Tijani Abubakar, Abdulsalam Olabisi, Aliyu Jibril, Simon Ereh and 4 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Ahmad Ibrahim Al-MustaphaDepartment of Veterinary Services, Kwara State Ministry of Agriculture and Rural Development, Ilorin, Kwara State, Nigeria; Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Ibadan, Oyo State, Nigeria; Infectious Diseases and One Health, Faculty of pharmaceutical Sciences, Universite de Tours, Tours, France. Electronic address: ahmad.al-mustapha@helsiniki.fi.
Ochulor OkechukwuInstitute of Virology, Hannover Biomedical Research School, 30625 Hannover, Germany.
Ademola OlayinkaDepartment of Medical Microbiology and Parasitology, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Osun state, Nigeria.
Oyeniyi Rasheed MuhammedDepartment of Public Health, Kwara State Ministry of Health, Ilorin, Kwara State, Nigeria.
Muftau OyewoDepartment of Veterinary Services, Kwara State Ministry of Agriculture and Rural Development, Ilorin, Kwara State, Nigeria; Nigerian Filed Epidemiology and Laboratory Training program, Asokoro, Abuja, Nigeria.
Samuel A OwoichoNigerian Filed Epidemiology and Laboratory Training program, Asokoro, Abuja, Nigeria; Federal Ministry of Agriculture and rural Development, Benin City, Edo State, Nigeria.
Ahmed Tijani AbubakarDepartment of Veterinary Services, Kwara State Ministry of Agriculture and Rural Development, Ilorin, Kwara State, Nigeria; African Center for Disease Control and Prevention, Abuja, Nigeria.
Abdulsalam OlabisiDepartment of Public Health, Kwara State Ministry of Health, Ilorin, Kwara State, Nigeria.
Aliyu JibrilFaculty of Veterinary Medicine, Usmanu Danfodiyo University, Sokoto, Nigeria.
Simon ErehDepartment of Internal Medicine, University of Calabar Teaching Hospital, Calabar, Cross River State, Nigeria.
Oluwatosin Enoch FakayodeDepartment of Public Health, Kwara State Ministry of Health, Ilorin, Kwara State, Nigeria.
Oluwaseun Adeolu OgundijoDepartment of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Ibadan, Oyo State, Nigeria.
Nusirat EleluDepartment of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Ilorin, Kwara State, Nigeria.
Victoria Olusola AdetunjiDepartment of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Ibadan, Oyo State, Nigeria.
Federal Ministry of Agriculture and Rural Development · NGUniversity of Ibadan · NGMedizinische Hochschule Hannover · DEObafemi Awolowo University · NGUniversité de Tours · FRUniversity of Calabar · NGUniversity of Ilorin · NGUsmanu Danfodiyo University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 vaccine is essential to reduce the global impact of the pandemic. Understanding its acceptance is key to Nigeria's national COVID-19 control strategies.

methodsBetween the 6th and 22nd of January 2021, we conducted a non-probability convenience sampling of 3076 respondents using online and in-person interviews to assess the prevalence and predictors of the COVID-19 vaccine acceptance in Nigeria.

findingsOf the 3076 recruited participants, 74.7% (n = 2300/3076) had tertiary education. The median age group was 30-39 years (35.1%, n = 1097/3076) whereas 31% (n = 952/3076) of all respondents had a monthly income<30,000 Naira (65 USD). The survey results indicated that a wide range of the respondents were in government employment (34.1%, n = 1050/3076). The majority of our study participants (92.2%, n = 2835/3076) believe that COVID-19 is real and not a hoax. Only 27.9% (n = 858/3076) of the study participants have been tested for COVID-19 and 17.8 % (n = 152/858) of the tested respondents were COVID-19 positive by PCR. Half (50.7%; n = 1560/3076) of the study participants were willing to take the vaccine once available. The majority of the respondents (81.1%, n = 2496/3076) were not willing to pay for the vaccine. Only 15.9% (n = 483/3076) of the respondents rated the government's handling of the pandemic above average. The potential acceptance of the COVID-19 vaccine was significantly affected by the age and the monthly income of the respondents. Respondents older than 60 years old (OR: 3.02, 95% CI: 1.69,5.41; p < 0.001) and those that earn between 250,000-500,000 Naira monthly (OR: 1.38; 95% CI: 1.11,1.70; p < 0.001) were more likely to accept the COVID-19 vaccine respectively. In addition, the respondents' perception of the existence of the disease (OR: 1.45; 95% CI: 0.99,2.18; p > 0.05), the need for a COVID-19 vaccine (OR: 16; 95% CI: 11.63,22.10; p < 0.001), the willingness to pay (OR: 1.68; 95% CI: 1.39,2.01; p < 0.001) and the rating of the government handling of the pandemic (OR: 2.25; 95% CI: 1.57,3.23; p < 0.001) were critical to the acceptance of the COVID-19 vaccine.

interpretationWith 50.7% vaccine acceptance, Nigeria's public health policymakers must prioritize and develop strategies that will effectively increase COVID-19 vaccine acceptance across the country with emphasis on trust, transparency and strong leadership.

Indexed as

COVID-19COVID-19 VaccinesAdultCross-Sectional StudiesHumansMiddle AgedNigeriaPatient Acceptance of Health CareSurveys and QuestionnairesCOVID-19 VaccinesCOVID-19NigeriaVaccine Acceptance

Identifiers

PMID35764433
PMCPMC9221949
OpenAlexW4283321164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.